AR110767A1 - PROLINAMIDE COMPOSITE REPLACED BY FENILDIFLUORMETILO - Google Patents
PROLINAMIDE COMPOSITE REPLACED BY FENILDIFLUORMETILOInfo
- Publication number
- AR110767A1 AR110767A1 ARP180100143A ARP180100143A AR110767A1 AR 110767 A1 AR110767 A1 AR 110767A1 AR P180100143 A ARP180100143 A AR P180100143A AR P180100143 A ARP180100143 A AR P180100143A AR 110767 A1 AR110767 A1 AR 110767A1
- Authority
- AR
- Argentina
- Prior art keywords
- cathepsin
- inhibitory effect
- prolinamide
- compound
- fenildifluormetilo
- Prior art date
Links
- VLJNHYLEOZPXFW-BYPYZUCNSA-N L-prolinamide Chemical compound NC(=O)[C@@H]1CCCN1 VLJNHYLEOZPXFW-BYPYZUCNSA-N 0.000 title 1
- 239000002131 composite material Substances 0.000 title 1
- 108090000613 Cathepsin S Proteins 0.000 abstract 3
- 102100035654 Cathepsin S Human genes 0.000 abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 abstract 2
- 206010020751 Hypersensitivity Diseases 0.000 abstract 2
- 206010052779 Transplant rejections Diseases 0.000 abstract 2
- 230000007815 allergy Effects 0.000 abstract 2
- 210000000988 bone and bone Anatomy 0.000 abstract 2
- 210000001185 bone marrow Anatomy 0.000 abstract 2
- 210000000056 organ Anatomy 0.000 abstract 2
- -1 proline compound Chemical class 0.000 abstract 2
- 208000005777 Lupus Nephritis Diseases 0.000 abstract 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000008383 nephritis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Un compuesto que tiene un efecto inhibidor de la catepsina S y puede utilizarse como un principio activo de una composición farmacéutica para prevenir y/o tratar enfermedades autoinmunes que incluyen lupus eritematoso sistémico (SLE) y nefritis lúpica, alergias, o rechazo de injertos de un órgano, médula ósea o tejido, y han hallado que un compuesto de prolinamida sustituida por fenildifluormetilo de la presente tiene el efecto inhibidor de la catepsina S, y de ese modo completa la presente. El compuesto de prolinamida sustituida por fenildifluormetilo de la presente tiene el efecto inhibidor de la catepsina S, y es útil como un agente para prevenir y/o tratar enfermedades autoinmunes que incluyen SLE y nefritis, alergias, o rechazo de injertos de un órgano, médula ósea o tejido.A compound that has a cathepsin S inhibitory effect and can be used as an active ingredient of a pharmaceutical composition to prevent and / or treat autoimmune diseases that include systemic lupus erythematosus (SLE) and lupus nephritis, allergies, or graft rejection of a organ, bone marrow or tissue, and have found that a phenylenedifluoromethyl substituted proline compound of the present has the inhibitory effect of cathepsin S, and thereby completes the present. The phenylenedifluoromethyl substituted prolinamide compound herein has the inhibitory effect of cathepsin S, and is useful as an agent to prevent and / or treat autoimmune diseases that include SLE and nephritis, allergies, or graft rejection of an organ, bone marrow. bone or tissue
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017010321 | 2017-01-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR110767A1 true AR110767A1 (en) | 2019-05-02 |
Family
ID=62979051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180100143A AR110767A1 (en) | 2017-01-24 | 2018-01-23 | PROLINAMIDE COMPOSITE REPLACED BY FENILDIFLUORMETILO |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US10322997B2 (en) |
| EP (1) | EP3575284B1 (en) |
| JP (1) | JP7001068B2 (en) |
| KR (1) | KR102553613B1 (en) |
| CN (2) | CN110248925B (en) |
| AR (1) | AR110767A1 (en) |
| AU (1) | AU2018211735B2 (en) |
| BR (1) | BR112019014788A2 (en) |
| CA (1) | CA3050224A1 (en) |
| CO (1) | CO2019009090A2 (en) |
| CY (1) | CY1124906T1 (en) |
| DK (1) | DK3575284T3 (en) |
| ES (1) | ES2892400T3 (en) |
| HR (1) | HRP20211613T1 (en) |
| HU (1) | HUE056920T2 (en) |
| IL (1) | IL268060B (en) |
| JO (1) | JOP20190181B1 (en) |
| LT (1) | LT3575284T (en) |
| MA (1) | MA47380A (en) |
| MX (1) | MX2019008756A (en) |
| MY (1) | MY195587A (en) |
| PH (1) | PH12019501645A1 (en) |
| PL (1) | PL3575284T3 (en) |
| PT (1) | PT3575284T (en) |
| RS (1) | RS62477B1 (en) |
| SG (1) | SG11201906777TA (en) |
| SI (1) | SI3575284T1 (en) |
| TW (1) | TWI764976B (en) |
| UA (1) | UA124036C2 (en) |
| WO (1) | WO2018139438A1 (en) |
| ZA (1) | ZA201904741B (en) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1482924E (en) * | 2002-03-05 | 2008-08-27 | Axys Pharm Inc | Cathepsin cysteine protease inhibitors |
| JP2010121918A (en) | 2008-11-17 | 2010-06-03 | Hiroyoshi Asada | Scorching preventing tool for handle portion of pan or the like |
| UA106748C2 (en) * | 2009-04-20 | 2014-10-10 | Ф. Хоффманн-Ля Рош Аг | Proline derivatives as cathepsin inhibitors |
| US7893099B2 (en) | 2009-06-11 | 2011-02-22 | Hoffman-La Roche Inc. | Cyclopentane derivatives |
| JP2012059507A (en) | 2010-09-08 | 2012-03-22 | Panasonic Corp | Connector structure between boards |
| US8524710B2 (en) * | 2010-11-05 | 2013-09-03 | Hoffmann-La Roche Inc. | Pyrrolidine derivatives |
| US8796471B2 (en) * | 2011-11-11 | 2014-08-05 | Hoffmann-La Roche Inc. | Process for the preparation of proline derivatives |
| US8802665B2 (en) * | 2012-02-17 | 2014-08-12 | Genentech, Inc. | Pyrrolidine derivatives |
| KR20150044947A (en) * | 2012-08-21 | 2015-04-27 | 에프. 호프만-라 로슈 아게 | Novel pyridine derivatives |
| WO2015051479A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
| CN105593230B (en) * | 2013-10-08 | 2018-07-06 | 默沙东公司 | Cathepsin cysteine protease inhibitors |
| SG11201807074VA (en) | 2016-02-26 | 2018-09-27 | Hoffmann La Roche | Novel pyrrolidine derivatives |
-
2018
- 2018-01-23 SG SG11201906777TA patent/SG11201906777TA/en unknown
- 2018-01-23 EP EP18744079.7A patent/EP3575284B1/en active Active
- 2018-01-23 JP JP2018564576A patent/JP7001068B2/en active Active
- 2018-01-23 DK DK18744079.7T patent/DK3575284T3/en active
- 2018-01-23 SI SI201830429T patent/SI3575284T1/en unknown
- 2018-01-23 UA UAA201908429A patent/UA124036C2/en unknown
- 2018-01-23 PL PL18744079T patent/PL3575284T3/en unknown
- 2018-01-23 MY MYPI2019004186A patent/MY195587A/en unknown
- 2018-01-23 AU AU2018211735A patent/AU2018211735B2/en active Active
- 2018-01-23 KR KR1020197021643A patent/KR102553613B1/en active IP Right Grant
- 2018-01-23 HU HUE18744079A patent/HUE056920T2/en unknown
- 2018-01-23 TW TW107102307A patent/TWI764976B/en active
- 2018-01-23 PT PT18744079T patent/PT3575284T/en unknown
- 2018-01-23 WO PCT/JP2018/001927 patent/WO2018139438A1/en active Application Filing
- 2018-01-23 CN CN201880008062.3A patent/CN110248925B/en active Active
- 2018-01-23 CN CN202010529596.XA patent/CN111574422B/en active Active
- 2018-01-23 HR HRP20211613TT patent/HRP20211613T1/en unknown
- 2018-01-23 LT LTEPPCT/JP2018/001927T patent/LT3575284T/en unknown
- 2018-01-23 RS RS20211299A patent/RS62477B1/en unknown
- 2018-01-23 MA MA047380A patent/MA47380A/en unknown
- 2018-01-23 BR BR112019014788-8A patent/BR112019014788A2/en not_active Application Discontinuation
- 2018-01-23 CA CA3050224A patent/CA3050224A1/en active Pending
- 2018-01-23 JO JOP/2019/0181A patent/JOP20190181B1/en active
- 2018-01-23 AR ARP180100143A patent/AR110767A1/en unknown
- 2018-01-23 MX MX2019008756A patent/MX2019008756A/en unknown
- 2018-01-23 ES ES18744079T patent/ES2892400T3/en active Active
- 2018-11-05 US US16/180,862 patent/US10322997B2/en active Active
-
2019
- 2019-04-25 US US16/394,571 patent/US10532979B2/en active Active
- 2019-07-15 IL IL268060A patent/IL268060B/en unknown
- 2019-07-15 PH PH12019501645A patent/PH12019501645A1/en unknown
- 2019-07-18 ZA ZA2019/04741A patent/ZA201904741B/en unknown
- 2019-08-22 CO CONC2019/0009090A patent/CO2019009090A2/en unknown
-
2021
- 2021-10-26 CY CY20211100928T patent/CY1124906T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022000250A1 (en) | Multi-specific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function substitution activity and pharmaceutical formulation containing such a molecule as an active ingredient (application divisional No. 202000767) | |
| UY38160A (en) | IMPLANTABLE PARTICLES AND RELATED METHODS | |
| CL2019000268A1 (en) | Cannabis composition. | |
| PH12020500500A1 (en) | Pyrazolopyrimidinone compounds and uses thereof | |
| CL2016001918A1 (en) | Heteroaryl amides as protein aggregation inhibitors | |
| CL2019003892A1 (en) | New azaquinoline derivatives. | |
| CL2020001797A1 (en) | Compounds, compositions and methods for treating diseases involving tissues with acidic or hypoxic diseases. | |
| MX2017014245A (en) | Compositions comprising mesenchymal stem cells and uses thereof. | |
| CO2019011877A2 (en) | New bicyclic pyrazole derivatives | |
| BR112017014361A2 (en) | methods for perfecting cell therapy | |
| CL2016002879A1 (en) | Pharmaceutical compositions for treating infectious diseases | |
| ECSP17045155A (en) | COMBINATIONS OF ACTIVE COMPOUNDS INCLUDING A DERIVATIVE OF (THIO) CARBOXAMIDE AND FUNGICIDE COMPOUNDS | |
| ECSP19077969A (en) | HETEROCYCLIC COMPOUND | |
| BR112019006880A2 (en) | compounds and compositions for treating leishmaniasis and methods of diagnosis and treatment using the same | |
| CL2018000430A1 (en) | Hydroxytriazine compound and related medical use. | |
| CL2017002803A1 (en) | Heterocyclic compounds and their use in the prevention or treatment of bacterial infections | |
| PH12021550122A1 (en) | Solubilized apyrases, methods and use | |
| BR112016008901A2 (en) | COMPOUNDS FOR USE IN THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES AND PAIN. | |
| AR110767A1 (en) | PROLINAMIDE COMPOSITE REPLACED BY FENILDIFLUORMETILO | |
| EA201491876A1 (en) | NITROGEN-CONTAINING BICYCLIC AROMATIC HETEROCYCLIC COMPOUND | |
| WO2018140707A8 (en) | Synergistic combination of thermolysin and an antibacterial agent to reduce or eliminate bacterial biofilms from surfaces | |
| SV2017005527A (en) | THERAPEUTIC AGENT FOR FRONT LOBBUS DYSFUNCTION | |
| MX2018003289A (en) | COMPOSITIONS AND METHODS OF USE OF ß-HYDROXY-ß-METHYLBUTYRATE (HMB) FOR ENHANCING RECOVERY FROM SOFT TISSUE TRAUMA. | |
| PE20181318A1 (en) | USE OF ISOTIANILO FOR CONTROL OF SPOTTED POTATO DISEASE | |
| BR112017005863A2 (en) | use of a composition, and, larvicidal treatment process |